Login to Your Account

Other News To Note

Wednesday, August 17, 2011
Qiagen NV, of Venlo, the Netherlands, and Pfizer Inc., of New York, inked a partnership to develop a molecular diagnostic test for use with Pfizer's investigational compound, dacomitinib (PF-00299804), an oral inhibitor of HER-1 (EGFR) and other tyrosine kinases that is in clinical development for the treatment of non-small-cell lung cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription